Equity Transactions - Additional Information (Details) - USD ($)					1 Months Ended				12 Months Ended
	Apr. 20, 2023	Oct. 06, 2022	Sep. 14, 2021	Sep. 09, 2021	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022	Jul. 01, 2023
Equity Transactions
Non-cash compensation expense recognized										$ 44,000
Common stock, par value (in dollars per share)					$ 0.00001					$ 0.00001	$ 0.00001
Research and development										$ 6,392,414	$ 5,784,862
Common stock, $0.00001 par value; 150,000,000 shares authorized, 11,698,497 and 11,592,173 shares issued and outstanding at June 30, 2023 and 2022, respectively.					$ 116					116	116
Increased additional paid in capital					11,596						11,596
TheraCour Pharma Inc
Equity Transactions
Accounts Payable					$ 679,397					733,434	679,397
TheraCour Pharma Inc | Related party
Equity Transactions
Research and development										2,535,862	2,369,022
Founder, Chairman and President | Related party
Equity Transactions
Employment agreement extension term (in years)		1 year
Preferred stock, par value (in dollars per share)												$ 0.00001
COVID 19 License Agreement | TheraCour Pharma Inc | Related party
Equity Transactions
Research and development	$ 157,000			$ 935,088						$ 157,000	935,088
Before Redomiciliation
Equity Transactions
Common stock, par value (in dollars per share)										$ 0.001
Number of shares issued on conversion of each share										1
Preferred stock, par value (in dollars per share)										$ 0.001
After Redomiciliation
Equity Transactions
Common stock, par value (in dollars per share)										$ 0.00001
Number of shares issued on conversion of each share										1
Preferred stock, par value (in dollars per share)										$ 0.00001
Warrants
Equity Transactions
Non-cash compensation expense recognized										$ 1,012	$ 4,215
Number of fully vested warrants granted to purchase shares of common stock										1,144	2,288
Warrants | Minimum
Equity Transactions
Exercise price (in dollars per share)					$ 1.46					$ 1.39	$ 1.46
Warrants | Maximum
Equity Transactions
Exercise price (in dollars per share)					$ 5.92					$ 3.40	$ 5.92
Director
Equity Transactions
Number of shares authorized					17,705					30,084	17,705
Stock-based compensation expense										$ 45,000	$ 52,500
Employee compensation
Equity Transactions
Number of shares authorized					3,572					3,572	3,572
Stock-based compensation expense										$ 4,822	$ 6,768
Consulting services
Equity Transactions
Number of shares authorized					38,863					72,668	38,863
Stock-based compensation expense										$ 108,000
Accounts Payable For Consulting Services
Equity Transactions
Accounts Payable					$ 35,750						$ 35,750
Accounts Payable For Consulting Services | Restricted Stock
Equity Transactions
Number of shares authorized					16,863						16,863
Common Stock | After Redomiciliation
Equity Transactions
Common stock, $0.00001 par value; 150,000,000 shares authorized, 11,698,497 and 11,592,173 shares issued and outstanding at June 30, 2023 and 2022, respectively.					$ 11,592					116	$ 11,592
Preferred Stock | After Redomiciliation
Equity Transactions
Preferred stock par value					$ 485					$ 5	$ 485
Series A Convertible Preferred Stock
Equity Transactions
Preferred stock, par value (in dollars per share)					$ 0.00001					$ 0.00001	$ 0.00001
Preferred stock par value					$ 5					$ 5	$ 5
Number of shares authorized					2,888						2,888
Series A Convertible Preferred Stock | Employee compensation
Equity Transactions
Stock-based compensation expense											$ 12,000
Series A Preferred Stock | Founder, Chairman and President | Related party
Equity Transactions
Shares granted		10,204	10,204		2,551	2,551	2,551	2,551
Number of shares vest on quarterly installments		2,551
Non-cash compensation expense recognized									$ 42,232		$ 109,000
Series A Preferred Stock | COVID 19 License Agreement | TheraCour Pharma Inc | Related party
Equity Transactions
Number of shares authorized for license milestone payment	50,000			100,000
Series A Preferred Stock | Employee compensation
Equity Transactions
Stock-based compensation expense										$ 26,418